Literature DB >> 9246043

Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.

H Senturk1, O Uzunalimoglu, Y Batur, I Simsek, A Mert, G Ozbay, H Cetinkaya, G Ersoz, F Tabak, H Akbaylar, M Akdogan, A Dokmeci, A Sonsuz, S Ozenirler, E Erden, N Tozum.   

Abstract

Interferon-alpha (IFN) and ursodeoxycholic acid (UDCA) combined have a controversial role in the treatment of chronic type C hepatitis. We studied the long-term efficacy of both drugs alone or in combination. In a three-year period, 108 patients were randomized into three treatment arms: (1) IFN alone 3 MU three times a week (N = 49), (2) IFN 3 MU three times a week + UDCA 250 mg twice a day (N = 45), and (3) UDCA alone 250 mg twice a day (N = 14). Response was defined as complete normalization of serum ALT. For the responders at the end of six months, the treatment was run to 12 months. Nonresponders (NRs) of the first group were crossed over to combination and NRs of the combination received 6 MU three times a week IFN+UDCA for the next six months. The enrollment to the UDCA alone arm was stopped early, since only 1/14 normalized serum ALT at the end of third month. However, 12/14 completed six months and 11 NRs received IFN 3 MU three times a week alone for the next six months. Twelve discontinued treatment due to side effects. Responders were followed-up untreated for 18 months. Sustained response (SR) was defined as persistence of normal serum ALT levels in this period. At the end of six months, 22/45 (48%) from the IFN-alone and 23/39 (58%) from the combination group responded. Twenty NRs from former and 15 of latter group were crossed over. While none of the 20 from the IFN-alone group responded to the combination, 1/15 NRs of the combination group responded to dose escalation. SR was achieved in 9/45 (20%) of the IFN alone and 7/39 (18%) of the combination group. The mean time form the end of the treatment to the relapse was not different between the groups. Five of 11 UDCA NRs responded to IFN with SR in 2. It was concluded that UDCA as a single agent is ineffective in achieving response in the treatment of chronic type C hepatitis. Combined with IFN, it increases response rate insignificantly although this is not sustained.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246043     DOI: 10.1023/a:1018854424403

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

Authors:  P R Galle; L Theilmann; R Raedsch; G Otto; A Stiehl
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

2.  The significance of blood transfusion in non-A, non-B chronic liver disease in Japan.

Authors:  K Kiyosawa; Y Akahane; A Nagata; Y Koike; S Furuta
Journal:  Vox Sang       Date:  1982-07       Impact factor: 2.144

3.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon.

Authors:  P Marcellin; N Boyer; C Degott; M Martinot-Peignoux; V Duchatelle; E Giostra; J Areias; S Erlinger; J P Benhamou
Journal:  Liver       Date:  1994-12

6.  Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.

Authors:  E Boucher; H Jouanolle; P Andre; A Ruffault; D Guyader; R Moirand; B Turlin; C Jacquelinet; P Brissot; Y Deugnier
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

7.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.

Authors:  N Hiramatsu; N Hayashi; A Kasahara; H Hagiwara; T Takehara; Y Haruna; M Naito; H Fusamoto; T Kamada
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

10.  A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C.

Authors:  Y Hakozaki; T Shirahama; M Katou; K Nakagawa; K Oba; K Mitamura
Journal:  Am J Gastroenterol       Date:  1995-08       Impact factor: 10.864

View more
  2 in total

Review 1.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

Review 2.  Bile acids for viral hepatitis.

Authors:  W Chen; J Liu; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.